Adjunctive Pharmacological Therapies in PCI : Antiplatelets and Anticoagulants
|
|
- Penelope Harrison
- 5 years ago
- Views:
Transcription
1 Adjunctive Pharmacological Therapies in PCI : Antiplatelets and Anticoagulants Young-Hak Kim, MD Asan Medical Center, Seoul, Korea
2 Why Drug? PCI localized therapy Drug systemic effect
3 Fate of Disrupted Atherosclerotic Plaque Active fissure Intramural thrombus Cholesterol, Smoking, Age, Hypercholesterol, Hypertension Healed fissure Further angina Occlusive thrombus Acute coronary occlusion Mural thrombus Intraintimal thrombus Unstable angina pectoris
4 Pathophysiology of AMI Rupture fibrous cap with luminal and intraplaque occlusive thrombus
5 Why Drug? Adjuntive drug therapy should be combined with PCI due to generalized inflammatory process of atheromatous plaque : Panvasculits
6 Target of Drug Thrombus Coagulation cascade Platelet RBC
7 Thrombogenesis after Vascular Injury Thrombin Xa-Va Prothrombin Xa X TF-Vlla Fibrinogen Tissue Factor Fibrin
8 Inactivation of Platelet Coagulation Fibrin Formation Primary Hemostasis Platelet Function Fibrinolysis Clot Dissolution Injured Vessel Wall Endothelium
9 Coagulation Cascade XII Anions XI Intrinsic Pathway Clot XIIa Ca 2 Ca 2 XIa IX IXa VIIIa Phospholipid Ca 2 X Thrombin Fibrin Tissue Factor (TF) VIIa/TF Phospholipid Fibrinopeptide A Xa Va Ca 2 PT Fragment F1,2 Fibrinogen VII Extrinsic Pathway Vit K dependent Heparin sensitive clotting factors LMWH sensitive clotting factors Direct antithrombin Prothrombin
10 Target of Drug Thrombus Coagulation cascade Platelet RBC
11 Thrombolysis The only dissolving drug of thrombus in real sense
12 Mechanism of Thrombolysis Fibrin Rich Thrombus Streptokinase/Plasminogen Complex Nonspecific systemic activation Plasminogen Plasmin D-dimers Thrombus specific activation Utilization of fibrinogen decreased its plasma levels TNK t-pa+fibrin t-pa+fibrinr-pa+fibrin PAI-1 Fibrin Degradation Products
13 TIMI Flow Rate and Mortality Pooled data from 5498 pts with thrombolysis % P=0.003 P< P< TIMI 0 or 1 TIMI 2 TIMI 3 TIMI=Thrombolysis in Myocardial Infarction Dr. Michael Gibson, 2000
14 Thrombolytic Agents First generation Streptokinase Urokinase Second generation Anistreplase(APSAC) Third generation Reteplase(r-PA) Lanoteplase (n-pa) TNK-t-PA Fibrin specificity Direct plaminogen activation Hemorrhagic stroke Cost Tissue-type PA(t-PA: alteplase, duteplase) Prourokinase (scu-pa: Plasma saruplase) half life Noncerebral bleeding Antigenecity
15 New Plasminogen Activators Alteplase (t-pa) Lanoteplase (n-pa) Reteplase (r- PA) Increment of patency rate Prolong plasma clearance single bolus injection Tenceteplase (TNK-tPA)
16 TIMI 3 Flow Rate at 90 min % Streptokinase Conventional dose tpa Accelerated dose tpa Double bolus alteplase
17 Thirty-day Mortality Rates Mortality (%) P=NS SK(IV) SK(SubQ) t-pa + SK t-pa Days from Randomization GUSTO-I trial Catch-up
18 Thirty-day Mortality Rate % Patients Depending on Thrombolytic Agents rpa npa TNK GUSTO III tpa Bolus lytic 6.18 In Time 2 ASSENT 2
19 Mortality Reduction Depending on Thrombolysis Time Mortality Reduction (%) MITI EMIP GISSI-1 ISIS-2 GISSI-1,ISIS-2 ASSET, AIMS LATE, EMERAS Hours LATE EMERAS
20 Target of Drug Thrombus Coagulation cascade Platelet RBC
21 Anticoagulants Unfractionated heparin Low molecular weight heparin Antithrombin
22 Heparin The most widely used anticoagulant
23 Coagulation Cascade XII Anions XI Intrinsic Pathway Clot XIIa Ca 2 Ca 2 XIa IX IXa VIIIa Phospholipid Ca 2 X Thrombin Fibrin Tissue Factor (TF) VIIa/TF Phospholipid Fibrinopeptide A Xa Va Ca 2 PT Fragment F1,2 Fibrinogen VII Extrinsic Pathway Vit K dependent Heparin sensitive clotting factors LMWH sensitive clotting factors Direct antithrombin Prothrombin
24 Optimal Activated Clotting Time During PCI Circulation. 2001;103:
25 Optimal Activated Clotting Time During PCI Circulation. 2001;103:
26 Low-Molecular Weight Heparin New drug expected to replace heparin
27
28 Coagulation Cascade XII Anions XI Intrinsic Pathway Clot XIIa Ca 2 Ca 2 XIa IX IXa VIIIa Phospholipid Ca 2 X Thrombin Fibrin Tissue Factor (TF) VIIa/TF Phospholipid Fibrinopeptide A Xa Va Ca 2 PT Fragment F1,2 Fibrinogen VII Extrinsic Pathway Vit K dependent Heparin sensitive clotting factors LMWH sensitive clotting factors Direct antithrombin Prothrombin
29 LMWH Preparation Ardeparin (Normiflo) Dalteparin (Fragmin) Enoxaparin (Lovenox) Nadroparin (Fraxiparine) Reviparin (Clivarine) Tinzaparin (Innohep)
30 Anti-Xa Activity After Enoxaparin in Pts Undergoing CAG & PCI Sustained antiplatelet activity Circulation 2001;103:658
31 ESSENCE trial ACS N=3171 Enoxaparin 1mg/kg bid 2-8 days (vs. UFH bolus infusion 2-8 days) End point:death, myocardial infarction, recurrent angina
32 ESSENCE / TIMI IIB ACS Comparison of Enoxaparin versus UFH in Patients with ACS having Subsequent PCI Group Death/MI/Urgent Revascularization at Day 43 Treatment n N % OR Treatment Effect 95% CI of OR p Value In-hospital UFH PCI Enoxaparin Ontreatment PCI UFH Enoxaparin
33 ESSENCE / TIMI IIB ACS Comparison of Enoxaparin versus UFH in Patients with ACS having Subsequent PCI Death/MI/Urgent Revascularization at One Year Treatment Effect Group Treatment n N % OR 95% CI of OR p Value In-hospital UFH PCI Enoxaparin Ontreatment PCI UFH Enoxaparin Am J Cardiol 2002;90:477
34 Short Term LMWH vs. ACS Unfractionated Heparin LMWH UFH OR 95% Cl Gurfinkel 0/68 4/70 (4 2%) FRIC 29/751 (3 9%) 26/731 (3 6%) ESSENCE 17/1607 (1 1%) 20/1564 (1 3%) TIMI 11B 33/1953 (1 7%) 42/1959 (2 1%) FRAXIS 69/2317 (3 0%) 36/1151 (3 1%) Pooled results 148/6696 (2 2%) 128/5475 (2 3%) LMWH better UFH better
35 ASSENT-3 PLUS AMI Death P=0.234 Recurrent MI P=0.028 Refractory Ischemia P=0.067 ICH P= % 7.5% 8% 8% 3% 6% 6.0% 6% 5.9% 6% 4.4% 6.5% 2% 2.2% 4% 4% 3.6% 4% 2% 2% 2% 1% 1.0% 0% 0% 0% 0% Enoxaparin UFH + TNK + TNK Enoxaparin UFH + TNK + TNK Enoxaparin UFH + TNK + TNK Enoxaparin UFH + TNK + TNK Wallentin et al, AHA 2002
36 A to Z study 3987 high-risk ACS patients were included (with ST changes or a positive cardiac marker) Pts obtained baseline therapy with tirofiban and aspirin Pts were randomized to enoxaparin (1mg/kg every 12 hours) or weight-adjusted UFH Treatment was given for a maximum of 120 hours but could be stopped or switched at any time at the treating physician s discretion 60% of the patients went for angiography ACC, 2003
37 Clinical end points End point Death MI Refractory ischemia Urgent revascularzation Multiple MI events Composite of secondary end points Enoxaparin (%) UFH (%) HR No significant reduction of cardiac events However, no sampling and expected efficacy 95% CI ACC, 2003
38 Direct Antithrombin Theoretically most attractive anticoagulant
39 Coagulation Cascade XII Anions XI Intrinsic Pathway Clot XIIa Ca 2 Ca 2 XIa IX IXa VIIIa Phospholipid Ca 2 X Thrombin Fibrin Tissue Factor (TF) VIIa/TF Phospholipid Fibrinopeptide A Xa Va Ca 2 PT Fragment F1,2 Fibrinogen VII Extrinsic Pathway Vit K dependent Heparin sensitive clotting factors LMWH sensitive clotting factors Direct antithrombin Prothrombin
40 Anti-thrombin Agents Direct Thrombin Inhibitors Do not require a cofactor Not inhibited by PF-4 or antiheparin proteins Effective against clot-bound thrombin No platelet aggregation Predictable anticoagulation No thrombocytopenia
41 Clinical Outcomes in PCI Bivalirudin Heparin better better Bivalirudin Heparin N=3277 N=2857 Death, MI or revasc. Death or MI MI Revascularization Hemorrhage 7.4% 13.0% 5.7% 7.5% 3.4% 4.4% 3.3% 4.3% 3.3% 4.8% 2.8% 7.6%
42 REPLACE PCI Patients Urgent or Elective PCI 1 : 1 randomization Aspirin Plavix Stent ANGIOMAX 0.75 mg/kg bolus 1.75mg/kg/h procedure Provisional abciximab or eptifibatide Heparin 65 U/kg Abciximab Or Eptifibatide Endpoints 30-day Death MI Revasc Hemorrhage Economics 1-year follow-up
43 Overall Outcome REPLACE - 2
44 REPLACE 2 : Drug Cost Drug Cost Heparin n=3008 Treated Total cost Aniomax n=2994 Treated Total cost Heparin Bivalirudin Abciximab Eptifibatide $ 10 $ 395 $ 1350 $ $28,960 $0 $1,741,500 $963, $0 $1,182,630 $143,100 $66,600 Total $2,734,060 $1,392,330 Average per patient Saving per patient $909 $465 > $400
45 Target of Drug Thrombus Coagulation cascade Platelet RBC
46 Thrombogenesis after Vascular Injury Thrombin Xa-Va Prothrombin Xa X TF-Vlla Fibrinogen Tissue Factor Fibrin
47 Antiplatelet Aspirin Clopidogrel or Ticlopidine Glycoprotein IIb/IIIa inhibitor
48 Pathways of Platelet Activation Epi PAF Thrombin Platelet ADP TXA2 Vasopressin 5HT GPIIb/IIIA Collagen Thrombus
49 Action of Antithrombotic Drug LMWH Heparin AT AT Bivalirudin Hirudins Argatroban Tissue factor Plasma clotting ADP cascade Thromboxane A 2 Prothrombin Factor Xa Thrombin Fibrinogen Aspirin Collagen Platelet activation Platelet aggregation Fibrin Ticlopidine Clopidogrel GP IIb/IIIa receptors Thrombolytics Thrombus
50 Aspirin Traditionally most important drug
51 Action of Antithrombotic Drug LMWH Heparin AT AT Bivalirudin Hirudins Argatroban Tissue factor Plasma clotting ADP cascade Thromboxane A 2 Prothrombin Factor Xa Thrombin Fibrinogen Aspirin Collagen Platelet activation Platelet aggregation Fibrin Ticlopidine Clopidogrel GP IIb/IIIa receptors Thrombolytics Thrombus
52 Cumulative Number of Vascular Deaths ISIS Control (13.2%) Aspirin (10.7%) Streptokinase (10.4%) Streptokinase + aspirin (8.0%) day ISIS-2 2 Investigators, LANCET 1988;2:
53 Clopidogrel or Ticlopidine New replacing drug of aspirin Plavix and Ticlid
54 Action of Antithrombotic Drug LMWH Heparin AT AT Bivalirudin Hirudins Argatroban Tissue factor Plasma clotting ADP cascade Thromboxane A 2 Prothrombin Factor Xa Thrombin Fibrinogen Aspirin Collagen Platelet activation Platelet aggregation Fibrin Ticlopidine Clopidogrel GP IIb/IIIa receptors Thrombolytics Thrombus
55 Platelet 1. Platelet Adhesion GP Ib 2. Platelet Activation Plaque rupture ASA, Clopidogrel/Ticlopidine Activated Platelet GP IIb/IIIa 3. Platelet Aggregation GP IIb/IIIa Inhibitors Cannon, Braunwald, Heart Disease 2001
56 Indirect Comparisons ASA Doses on Vascular Events in High Risk Patients ASA Dose # Trials OR mg 34 19% mg 19 26% mg 12 32% <75 mg 3 13% Overall 65 23% Antiplatelet Antiplatelet Better Worse Antithrombotic Trialists Collaboration BMJ 2002; 324:71-86
57 Antiplatelet Therapy Trialists and CAPRIE Studies ASA and Clopidogrel in Secondary Prevention Cumulative Event Rate - % (Vascular Death, MI, or Stroke p = Time from Randomization (mo) 1 Antiplatelet Trialists Collaboration. BMJ. 1994; 308: CAPRIE Steering Committee, Lancet ;348: Placebo 1 Aspirin 1,2 Clopidogrel 2 25% 8.7% Relative Risk Reduction
58 Efficacy of Clopidogrel or Ticlopidine in Reducing Coronary Events after Stenting 30-Day Major Adverse Cardiac Events Trial N Relative Risk & 95% CI Clopid. Ticl. CLASSICS 1, % 0.9% TOPPS % 3.5% Müller % 1.7% CCF 2, % 8.9% Lenox Hill 2, % 3.8% Mayo 2, % 1.6% N. Memorial 1, % 2.2% S. Illinois % 1.4% Wash. Hosp % 0.5% Wessex % 5.2% Overall 13,827 OR = 0.73, p= % 3.9% Clopidogrel Better Ticlopidine Better Bhatt, DL. JACC. 2002
59 Benefit of Pre-treatment with Clopidogrel 30 Days (D/MI/UTVR) 6 Months (D/MITVR) Clopidogrel No Clopidogrel
60
61 Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Randomized, Double-blind 12, 562 patients Clopidogrel 300mg loading dose, 75 mg daily Patients with Non-ST elevation Acute Coronary Syndrome R Aspirin mg 3 months of double-blind Rx, 12 months of F/U Aspirin mg Placebo Months CURE Investigators NEJM 2001
62 Cumulative Hazard Rates for CV Death/MI/Stroke CURE Investigators NEJM 2001 Cumulative Cumulative Hazard Hazard Rates Placebo P < Clopidogrel No of Pts of Follow-up Months of Follow-up Plac Clop
63 PCI- CURE Study Design CURE PCI-CURE PLACEBO + ASA * Pretreatment N = 2,658 patients undergoing PCI Open-label thienopyridine N = 1345 R PCI 30 days post PCI End of follow-up Up to 12 months after randomization CLOPIDOGREL + ASA * Pretreatment Open-label thienopyridine N = 1313 Mehta, SR. et al for the CURE Trial Investigators. N Engl J Med. 2001;345:
64
65 PCI- CURE Overall Long-term Results Cumulative Hazard Rate CV Death or MI from randomization to end of follow-up * In addition to other standard therapies. Placebo + ASA* Clopidogrel + ASA* Mehta et al for the CURE Investigators. Lancet. 2001;358: % 8.8% P = N = Days of follow-up 31% Relative Risk Reduction
66 Major/Life-Threatening Bleeds within 7 Days of CABG Surgery Plac Clop RR p Stopped < 5 days prior to CABG Pts with Maj/LT Bleeds N = % N = % Stopped > 5 days prior to CABG Pts with Maj/LT Bleeds N = % N = %
67 Clopidogrel timing Early treatment - Reduced early ischemic events - Potential for bleeding if early CABG needed Wait until catheterization - Avoid treatment of patients pre-cabg - Lost opportunity for early benefit
68 Clinical Events Post-PCI Elective PCI STENT ACS - Invasive Traditional clopidogrel Evidence-Based: CURE/ PCI-CURE/ CURE/ CREDO 24 Hours Acute Incidence: Stent 0.6% Thrombosis Subacute Stent Thrombosis Stent: Restenosis Coronary tree: recurrent events Up to 30 days Incidence: 6.4% Up to 12 Months Incidence: 20-25%* Incidence: 6-15% Major Adverse Cardiac Events Years Incidence: ~ 20%
69 Glycoprotein IIb/IIIa Inhibitors Abciximab : Reopro Tirofiban : Agrastat
70 Embolized Platelet Aggregate in a Small Myocardial Arteriole Stains intensely red for the IIb/IIIa IIIa receptor
71 Potent Antiplatelet Effect Epi 5HT PAF Thrombin Platele t GPIIb/IIIa Thrombus ADP TXA2 Vasopress in Collagen GPIIb/IIIa Blocker
72 Fibrinogen or vwf Platelet GP IIb/IIIa Vitronectin Endothelium Collagen vwf
73 GP IIb/IIIa Inhibitor During Medical Management and After PCI: CAPTURE, PURSUIT, PRISM-PLUS Medical Rx Post PCI Death or MI 10% 8% 6% 4% 2% N=12,296 N=2754 P=0.001 Control P=0.001 GP IIb/IIIa inhibitor 4.3% 2.9% 8.0% 4.9% 0% h +48 h +72 h +24 h +48 h PCI Boersma et al. Circulation ;100:
74 Benefit of GP IIb/IIIa inhibitors by PCI Treatment for 12 hours Roffi M. et al. EHJ 2002; 105:
75 Upstream vs. Downstream GP IIb/IIIa inhibition Upstream demonstrated benefits Thrombus, TIMI 3, MI size (PRISM-PLUS) PLUS) Death/MI pre-cath (meta-analysis) analysis) Events Med Rx, PCI, or CABG TACTICS-TIMI TIMI 18 benefit of strategy Downstream with abciximab potential in ACS 50% benefit in PCI (EPISTENT) Abciximab mortality (EPISTENT, meta) Abcixmab restenosis/tvr in DM (EPISTENT) BUT: TARGET No diff mortality, TVR
76 PRISM-PLUS: Improvement in Thrombus Grade and TIMI Flow Grade with IIb/IIIa inhibition % Odds Ratio: 0.77 P=0.022 Possible Small Moderate Large Occlusion Tirofiban + Heparin (n=608) 17% Possible Small Moderate Large Occlusion Heparin (n=622) 24% Effective in large thrombotic burden 5 0 Odds Ratio 0.65 P= % Partial Perfusion (TIMI 2) Total Occlusion (TIMI 0) Tirofiban + Heparin (n=570) 25.5% Partial Perfusion (TIMI 2) TIMI 1 Total Occlusion (TIMI 0) Heparin (n=580) Zhao et al. Circulation 1999;100:
77 IIb/IIIa IIIa Inhibition in TnI + patients by Revasc: PRISM Study Death / MI at 30 Days 0.37 ( ) 0.93) P= ( ) 0.84) P=0.004 Heeschen, et al. Lancet 1999;354:
78 PRISM-PLUS: Risk of D/MI/RI by TIMI Risk Score and PCI No PCI TIMI RISK High N 664 P 0.04 Low PCI High Low Tiro + Hep 1 Heparin 10 Better Better Morrow DA et al. AHA 2001
79 TIMI 3 Flow Rate CADILAC Trial 2681 pts with AMI < 12hr % P=NS 20 0 PTCA N=518 PTCA+Abc N=528 Stent N=512 Stent+Abc N=524 Stone GW et al, NEJM 2002;346:
80 12-Month Mortality in Primary Angioplasty for Acute Myocardial Infarction CADILAC Trial 6% 5.5% 5.4% 4% 2% No significant benefit of reopro 3.4% 3.1% 0% Months to Event P=0.10 Stone GW et al, NEJM 2002;346:
81 12-Month MACE in Primary Angioplasty for Acute Myocardial Infarction CADILAC Trial MACE=death, MI, Target lesion revascularization 25% 20% PTCA, no Ab PTCA, Ab Stent, no Ab 22.4% 20.6% 15% 10% 5% 0% 0 No significant benefit of reopro Months to Event P=0.10 P< % 13.3% Stone GW et al, NEJM 2002;346:
82 Angiographic Restenosis Restenosis P< % 40.8% % % 20.8 CADILLAC Trial Reocclusion No significant benefit of reopro % P= % P P+A S S+A P P+A S S+A Stone GW et al, NEJM 2002;346:
83 30-Day Subacute Thrombosis CADILLAC Trial % P=0.05 Slight benefit of reopro P= PTCA PTCA+Abc Stent Stent+Abc Stone GW et al, NEJM 2002;346:
84 30-Day Hemorrhagic Complications Abciximab (+) % 8 Abciximab (-) P= Thrombocytopenia CADILLAC Trial 5.4 P=0.05 Increased bleeding rate of reopro 3.4 Transfusion Stone GW et al, NEJM 2002;346:
85 Based on Site of Initiation of Treatment % 30 P<0.05 ADMIRAL Trial Death, MI, and TVR P<0.05 Stent + placebo (n=151) Stent + Abciximab (n= Early treatment is important P=NS P=NS days In Ambulance or ER (n=86) In Cath lab or CCU (n=214) TVR=Target vessel revascularization months 30 days 6 months Montalescot et al, NEJM 2001;344:
86 Conclusions Anticoagulants Heparin Low molecular weight heparin Direct thrombin inhibitor Antiplatelets Aspirin Ticlopidine Clopidogrel Glycoprotein IIb/IIIa inhibitor Antithrombotic activity Bleeding risk
Update on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationColumbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
More informationNovel Anticoagulation Therapy in Acute Coronary Syndrome
Novel Anticoagulation Therapy in Acute Coronary Syndrome Soon Jun Hong Korea University Anam Hospital 1 Thrombus Formation Cascade Coagulation Cascade Platelet Cascade TXA2 Aspirin R Inhibitor Fondaparinux
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationIndex. Hematol Oncol Clin N Am 19 (2005) Note: Page numbers of article titles are in boldface type.
Hematol Oncol Clin N Am 19 (2005) 203 208 Index Note: Page numbers of article titles are in boldface type. A Abciximab, as an antiplatelet agent, 93 94 Acute coronary syndromes, use of antiplatelet drugs
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationTiming of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More informationAntiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Franz-Josef Neumann Herz-Zentrum Bad Krozingen Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
More informationIs there a real need for new agents to optimize efficacy/safety balance
Anticoagulation in acute coronary syndrome Is there a real need for new agents to optimize efficacy/safety balance Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures
More informationDirect Thrombin Inhibitors and Gp 2b/3a Receptor Blockers in the Cardiac Cath Lab. Eric J Dippel, MD FACC
Midwest Cardiovascular Research Foundation Direct Thrombin Inhibitors and Gp 2b/3a Receptor Blockers in the Cardiac Cath Lab Eric J Dippel, MD FACC Plaque Rupture Stable Angina Unstable Angina Non Q-wave
More informationDirect Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Charles A. Simonton MD, FACC, FSCAI Sanger Clinic Medical Director Clinical Innovation and Research Carolinas Heart
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationPathophysiology of ACS
Pathophysiology of ACS ~ 2.0 MM patients admitted to CCU or telemetry annually 0.6 MM ST-segment elevation MI 1.4 MM Non-ST-segment elevation ACS NSTEMI vs STEMI VANQWISH Boden et al N Engl J Med 1998;338:1785-1792
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationC.R.E.D.O. Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial
Clopidogrel for the Reduction of Events During Observation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial From Steinhubl et al, JAMA 2002;228:2411-20
More informationCHAPTER 17 Antithrombotic Agents Heparins
CHAPTER 17 Antithrombotic Agents Heparins Structure Mechanism of Action Pharmacokinetics Limitations of Unfractionated Heparin Heparin Induced Thrombocytopenia Heparin Rebound Low Molecular Weight Heparins
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationNOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationFacilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?
Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction Is it beneficial to patients? Seung-Jea Tahk, MD. PhD. Suwon, Korea Facilitated PCI.. background Degree of coronary flow at
More informationPart IV Antithrombotics, Anticoagulants and Fibrinolytics
Part IV Antithrombotics, Anticoagulants and Fibrinolytics "The meaning of good and bad, of better and worse, is simply helping or hurting" Emerson Chapter 16: Blood Coagulation and Fibrinolytic System
More informationAnticoagulation Update David J. Moliterno, MD
David J., MD Anticoagulant Agents n Cardiovascular Medicine: An Update David J., MD Professor and Chairman Division of Cardiovascular Medicine The University of Kentucky Linda and Jack Gill Heart nstitute
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More informationUpdate on the management of STEMI. Elliot Rapaport, M.D. San Francisco, CA December 14, 2007
Update on the management of STEMI Elliot Rapaport, M.D. San Francisco, CA December 14, 2007 Universal MI Definition Committee 2007 Recommendations Type 1 Spontaneous MI associated with ischemia and due
More informationChapter 15 Glycoprotein IIb/IIIa Antagonists
Chapter 15 Glycoprotein IIb/IIIa Antagonists Introduction - GP IIb/IIIa receptors - Pharmacologic approaches - Preparations and dosages Mechanism of Action Clinical Efficacy - UA / NSTEMI - STEMI - PCI
More informationPlatelet-fibrin clot. 50Kd STEMI. Abciximab. Video of a IIb/IIIa inhibitor in action. Unstable Angina and non-stsegment
Objectives IIb/IIIa, Vitamin K, and Direct Thrombin Inhibition in Cardiology Michael Gulseth, Pharm. D., BCPS Assistant Professor, Duluth Pharmacy 6122 February 14, 2005 Describe the pharmacology, kinetics,
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More informationClopidogrel When For What For How Long. T Benjanuwattra Chiang Mai Heart Cent
Clopidogrel When For What For How Long T Benjanuwattra Chiang Mai Heart Cent Evidence Based Medicine I don t want to put you to sleep But want you to be fully alert Atherothrombosis: A Generalized and
More informationQuinn Capers, IV, MD
Heart Attacks Mended Hearts Presentation, January, 2017 Quinn Capers, IV, MD Associate Professor of Medicine (Cardiovascular Medicine) Director, Transradial Coronary Interventions Division of Cardiovascular
More informationAgents for Peripheral Vascular Disease & Thrombosis
Agents for Peripheral Vascular Disease & Thrombosis Edward JN Ishac, Ph.D. Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia Campus
More informationAgents for Peripheral Vascular Disease & Thrombosis
Agents for Peripheral Vascular Disease & Thrombosis Edward JN Ishac, Ph.D. Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia Campus
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department
ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department decision-making. They have become the cornerstone of many ED protocols for
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationAcute Coronary Syndrome. ACC/AHA 2002 Guidelines
Acute Coronary Syndrome ACC/AHA 2002 Guidelines ACS Unstable Angina Non ST elevation MI ST elevation MI ACS UA and Non STEMI described in these guidelines Management of STEMI described in separate guidelines
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationThe Myth of Class Effect Antithrombotics Christopher Cannon, MD
The Myth of Class Effect Antithrombotics Christopher Cannon, MD Cardiovascular Division Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Senior Investigator, TIMI Study
More informationAcute coronary syndrome (ACS) is an
OVERVIEW OF MEDICAL MANAGEMENT OF ACUTE CORONARY SYNDROMES Robert B. Parker, PharmD * Acute coronary syndrome (ACS) is an umbrella term used to describe any group of symptoms of acute myocardial ischemia
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationCurrent Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach
Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants
More informationBivalirudin should be indicated for all patients with STEMI. Adnan Kastrati Deutsches Herzzentrum, Munich, Germany
Bivalirudin should be indicated for all patients with STEMI Adnan Kastrati Deutsches Herzzentrum, Munich, Germany 1 Heparin+IIb/IIIa, heparin alone or bivalirudin in STEMI: Do we have the answer? 2 Heparin+IIb/IIIa,
More informationManagement of Acute Myocardial Infarction
Management of Acute Myocardial Infarction Prof. Hossam Kandil Professor of Cardiology Cairo University ST Elevation Acute Myocardial Infarction Aims Of Management Emergency care (Pre-hospital) Early care
More informationPrimary PCI in patients with STEMI Abbott Vascular. All rights reserved.
Primary PCI in patients with STEMI Primary PCI in patients with STEMI Agenda 2 Primary PCI in patients with STEMI Definition: angioplasty ± stenting without prior or concomitant fibrinolytic therapy Objectives
More informationSTEMI: Newer Aspects in Pharmacological Treatment
CHAPTER 14 STEMI: Newer Aspects in Pharmacological Treatment P. C. Manoria, Pankaj Manoria Introduction ST elevation myocardial infarction (STEMI) commonly results from disruption of a vulnerable plaque
More informationThrombolysis, adjunctive pharmacology and interventions
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation ESC Annual Congress Munich, 2012 Thrombolysis, adjunctive pharmacology and interventions
More informationOptimal antithrombotic therapy:
Optimal antithrombotic therapy: upstream and during primary PCI. Steen D Kristensen, MD, DMSc, FESC Professor and Consultant Interventional Cardiologist Aarhus University, Denmark UNIVERSITY OF AARHUS
More informationMortality from ST-segment elevated acute
Choosing Pharmacotherapy for Primary PCI in Acute Myocardial Infarction A review of the agents and strategies commonly used during percutaneous intervention for ST-segment elevated myocardial infarction.
More informationBlood Thinner Agent. Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy
Blood Thinner Agent Done by: Meznah Al-mutairi Pharm.D Candidate PNU Collage of Pharmacy Outline: Blood thinner agent definition. anticoagulants drugs. Thrombolytics. Blood thinner agent Therapeutic interference
More informationAcute Coronary Syndromes. January 9, 2013 Chris Chiles M.D. FACC
Acute Coronary Syndromes January 9, 2013 Chris Chiles M.D. FACC Disclosures None- not even a breakfast burrito from a drug company Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes* 1.57
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationManagement of Acute Coronary Syndromes
Management of Acute Coronary Syndromes Objectives 1. To outline the approach in managing a patient who presents with an acute coronary syndrome focusing on anti- thrombotic agents. Jenny Chiu, BScPhm,
More informationAntiplatelet Therapy: how, why, when? For Coronary Stenting
Antiplatelet Therapy: how, why, when? For Coronary Stenting Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University of Florida
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationAcute Myocardial Infarction 2004 Update
Acute Myocardial Infarction Update Acute Myocardial Infarction Update The Scope of the Problem Adjunctive Therapy The Lost Art of Thrombolysis Alan Keith Berger, MD Divisions of Cardiology and Epidemiology
More informationA Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI
HORIZONS-AMI: A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Gregg W. Stone
More informationAntiplatelet therapy and Coronary Interventions. Georgios I. Papaioannou, MD Hartford Hospital Grand Rounds 4/22/2003
Antiplatelet therapy and Coronary Interventions Georgios I. Papaioannou, MD Hartford Hospital Grand Rounds 4/22/2003 Objectives Pharmacology of GP IIb/IIIa inhibitors and Monitoring of Platelet Inhibition
More informationThrombolysis in Acute Myocardial Infarction
CHAPTER 70 Thrombolysis in Acute Myocardial Infarction J. S. Hiremath Introduction Reperfusion of the occluded coronary artery at the earliest is the most important aim of management of STEMI. Once a flow
More informationTreatment of Acute Coronary Syndromes
Treatment of Acute Coronary Syndromes UC SF Jeffrey Tabas, M.D. sf g h Associate Professor UCSF School of Medicine Emergency Services, San Francisco General Hospital Objectives Review the updated AHA/ACC
More informationThe Long and Winding Road:
Invited Article The Long and Winding Road: The Management of Acute Coronary Syndromes in Malta Robert G. Xuereb, Mariosa Xuereb Abstract The treatment of acute coronary syndromes in Malta has been revolutionized
More information2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY
2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY Charles V. Pollack, Jr., MA, MD, FACEP, FAAEM, FAHA Professor and Chairman, Department of Emergency
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationM/39 CC D. => peak CKMB (12 hr later) ng/ml T.chol/TG/HDL/LDL 180/150/48/102 mg/dl #
Acute Coronary Syndrome - Case Review - Young-Guk Ko, MD Yonsei Cardiovascular Center Yonsei University College of Medicine Case 1 M/39 #4306212 CC D : Severe squeezing chest pain : 4 hours, aggravated
More information(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris
Early aggressive versus initially conservative strategy in elderly patients with non-st- elevation acute coronary syndrome: the Italian randomised trial (ClinicalTrials.gov ID: NCT00510185) Stefano Savonitto,
More informationIs the role of bivalirudin established?
Is the role of bivalirudin established? Rob Henderson Consultant Cardiologist Trent Cardiac Centre Nottingham University Hospitals Conflicts of Interest: None Declarations: Member NICE Unstable Angina
More informationThe restoration of coronary flow after an
Pharmacological Reperfusion in Acute Myicardial Infarction after ASSENT 3 and GUSTO V [81] DANIEL FERREIRA, MD, FESC Serviço de Cardiologia, Hospital Fernando Fonseca, Amadora, Portugal Rev Port Cardiol
More informationAn Update on Oral Anti-platelet therapy in patients with non-st Myocardial Infarction. Disclosures
An Update on Oral Anti-platelet therapy in patients with non-st Myocardial Infarction R. Scott Wright, MD, FACC, FESC, FAHA, Professor of Medicine Mayo Clinic Fall Managed Care Forum November 2013 3098590-1
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationThe use of percutaneous coronary intervention (PCI) as
Antithrombotic Therapy During Percutaneous Coronary Intervention The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Jeffrey J. Popma, MD; Peter Berger, MD; E. Magnus Ohman, MD, FCCP;
More informationOral Anticoagulant Drugs
Oral Anticoagulant Drugs Spoiled sweet clover caused hemorrhage in cattle(1930s). Substance identified as bishydroxycoumarin. Initially used as rodenticides, still very effective, more than strychnine.
More informationManual of Interventional Cardiology
782 PLATELET GLYCOPROTEIN IIb/IIIa RECEPTOR ANTAGONISTS (Tables 34.15, 34.16) Activation of the platelet glycoprotein (GP) IIb/IIIa receptor complex constitutes the final common pathway for platelet aggregation,
More informationThe Role of Low-Molecular-Weight Heparin in the Management of Acute Coronary Syndromes
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02901-7
More informationAnticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT
Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet
More informationStent Thrombosis Importance of Pharmacotherapy
Stent Thrombosis Importance of Pharmacotherapy George D. Dangas, MD, FSCAI Columbia University Medical Center Cardiovascular Research Foundation New York City SCAI-2007 Orlando, FL Presenter Disclosure
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationBivalirudin Clinical Trials Update Evidence and Future Perspectives
Bivalirudin Clinical Trials Update Evidence and Future Perspectives Andreas Baumbach Consultant Cardiologist/ hon. Reader in Cardiology Bristol Heart Institute University Hospitals Bristol MY CONFLICTS
More informationPrimary Exam Physiology lecture 5. Haemostasis
Primary Exam Physiology lecture 5 Haemostasis Haemostasis Body s response for the prevention and cessation of bleeding. Broadly consists of: Primary Haemostasis - vascular spasm and platlet plug formation
More informationClopidogrel and ASA after CABG for NSTEMI
Clopidogrel and ASA after CABG for NSTEMI May 17, 2007 Justin Lee Pharmacy Resident University Health Network Objectives At the end of this session, you should be able to: Explain the rationale for antiplatelet
More informationMyocardial Infarction In Dr.Yahya Kiwan
Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationPOCT in the Management of Antiplatelet Therapy Patient Response, Treatment Optimization and Personalized Medicine
POCT in the Management of Antiplatelet Therapy Patient Response, Treatment Optimization and Personalized Medicine Jackie Coleman, Ph.D. Director of Scientific Affairs Accumetrics, Inc. San Diego, CA Goals
More informationAnti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib!
Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib! Roxana Mehran, MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Research support
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationקורס השתלמות לאחיות ו טכ נאים מחדרי צנתור תרופות נוגדות קרישה וטסיות בחולים העוברים צנתור כלילי התערבותי
קורס השתלמות לאחיות ו טכ נאים מחדרי צנתור 06/2010 תרופות נוגדות קרישה וטסיות בחולים העוברים צנתור כלילי התערבותי בי""י ד"ר אלי לב מנהל שרות הצנתורים רבין מרכז רפואי ח השרון, 3 Major systems involved in
More informationThrombosis. Jeffrey Jhang, M.D.
Thrombosis Jeffrey Jhang, M.D. Introduction The human hemostatic system has evolved to maintain blood flow under normal physiologic conditions while remaining primed to rapidly respond to vascular injury
More informationDRUGS USED IN COAGULATION DISORDERS
DRUGS USED IN COAGULATION DISORDERS Course: Integrated Therapeutics 1 Lecturer: Dr. E. Konorev Date: November 1, 2010 Materials on: Exam #6 Required reading: Katzung, Chapter 34 1 DISORDERS OF COAGULATION
More informationSession Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia
GROUPE HOSPITALIER BICHAT-CLAUDE BERNARD PARIS DIDEROT UNIVERSITY - PARIS 7 Session Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia Pierre Amarenco INSERM U-698 and Denis
More informationST-Elevation MI: Update on Bivalirudin and DES
ST-Elevation MI: Update on Bivalirudin and DES George D. Dangas, MD, FACC, FSCAI, FAHA Professor of Medicine Director, Cardiovascular Innovation Mount Sinai Medical Center, New York, NY Disclosure Research
More informationAcute Coronary Syndrome: Interventional Strategy
2005 Acute Coronary Syndrome: Interventional Strategy Youngkeun Ahn, MD, PhD, FACC, FSCAI Department of Cardiology Program in Gene and Cell Therapy, The Heart Center of Chonnam National University, GwangJu,,
More information9/24/2013. Thrombolytics in 2013: Never Say Never. September 19 th, 2013 Scott M Lilly, MD PhD. Clinical Case
September 19 th, 2013 Scott M Lilly, MD PhD Thrombolytics in 2013: Never Say Never Clinical Case 2 1 Evolution of STEMI Therapy The importance of absolute rest in bed for several days is clear James B
More informationPlatelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
European Heart Journal (00) 3, 1441 1448 doi:10.1053/euhj.00.3160, available online at http://www.idealibrary.com on Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes Gradient of benefit
More informationEffect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationIs Cangrelor hype or hope in STEMI primary PCI?
Is Cangrelor hype or hope in STEMI primary PCI? ARUN KALYANASUNDARAM MD, MPH, FSCAI HOPE Issues with platelet inhibition in STEMI Delayed onset In acute settings, achieving the expected antiplatelet effect
More informationIssues in the Management of Diabetic Patients with Cardiovascular Disease
Issues in the Management of Diabetic Patients with Cardiovascular Disease Elliot Rapaport, MD December 13, 2008 1 Hyperglycemia and Acute Coronary Syndromes 2 Effect of Hyperglycemia in STEMI Impairs microvascular
More information